We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.30 | 64.85 | 65.53 | 64.33 | 65.51 | 7,822,721 | 05:00:04 |
From May 2019 to May 2024
By Michael Dabaie
Gilead Sciences Inc. (GILD) said it will collaborate with insitro to develop nonalcoholic steatohepatitis therapies.
Under the three-year agreement, insitro's platform will be used to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease, Gilead said Tuesday.
Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development.
Insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. Insitro will be eligible to receive up to $200 million for the achievement of milestones for each of the five Gilead targets and up to low double-digit tiered royalties on net sales.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 16, 2019 07:41 ET (11:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
